Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 7,674 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $45.00, for a total transaction of $345,330.00. Following the transaction, the director now directly owns 310,978 shares of the company's stock, valued at approximately $13,994,010. This trade represents a 2.41 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
NASDAQ:PDEX traded up $3.41 during trading hours on Tuesday, hitting $47.78. The company's stock had a trading volume of 66,240 shares, compared to its average volume of 32,979. Pro-Dex, Inc. has a 52-week low of $16.83 and a 52-week high of $59.60. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $155.81 million, a P/E ratio of 23.77 and a beta of 0.68. The stock has a fifty day moving average of $39.93 and a 200-day moving average of $37.76.
Pro-Dex (NASDAQ:PDEX - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. On average, equities analysts forecast that Pro-Dex, Inc. will post 2 earnings per share for the current year.
A number of research firms recently weighed in on PDEX. Ascendiant Capital Markets increased their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a "buy" rating in a research report on Monday, November 11th. StockNews.com lowered Pro-Dex from a "strong-buy" rating to a "buy" rating in a report on Monday, February 3rd.
Check Out Our Latest Analysis on Pro-Dex
Several institutional investors have recently modified their holdings of the stock. Northern Trust Corp grew its position in shares of Pro-Dex by 14.1% in the 4th quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier's stock valued at $1,672,000 after buying an additional 4,426 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier's stock worth $819,000 after purchasing an additional 2,296 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier's stock valued at $740,000 after purchasing an additional 529 shares during the last quarter. EAM Investors LLC acquired a new stake in shares of Pro-Dex in the 4th quarter valued at about $1,047,000. Finally, O Shaughnessy Asset Management LLC purchased a new position in Pro-Dex during the 4th quarter worth approximately $995,000. Hedge funds and other institutional investors own 15.28% of the company's stock.
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Pro-Dex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pro-Dex wasn't on the list.
While Pro-Dex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.